Abstracts tagged "Biomarkers"

Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…
Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Jia Shi¹, Yang Wu¹, Ting Wang², Chen Yu³, qian wang⁴, Xinping Tian⁵, Mengtao Li⁴, Kristen Demoruelle⁶, Joshua Solomon⁷ and Christian Lood², ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷National Jewish Health, Denver, CO
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1202 • ACR Convergence 2024
Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression
Afshin Jamshidi¹, Osvaldo Espin-Garcia², Thomas G. Wilson³, Ian Loveless³, Jean-Pierre Pelletier¹, Amanda Ali⁴ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Epidemiology and Biostatistics, University of Western Ontario; Dalla Lana School of Public Health and Department of Statistical Sciences, University of Toronto; Department of Biostatistics, Schroeder Arthritis Institute; Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, ⁴Henry Ford Health + Michigan State University Health Sciences; Center for Molecular Medicine and Genetics, Wayne State University, Montreal, QC, Canada
Background/Purpose: The development of knee osteoarthritis (OA) is generally characterized by a slow evolution. However, its progression and severity may occur rapidly in some individuals.…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1691 • ACR Convergence 2024
Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Elizabeth Volkmann¹, Holly Wilhalme², Donald Tashkin², Grace Kim², Jonathan Goldin², Alana Haussmann², Masataka Kuwana³, Michael Roth² and Shervin Assassi⁴, ¹University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ²UCLA, Los Angeles, ³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁴UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Despite the expanding treatment landscape for systemic sclerosis-associated interstitial lung disease (SSc-ILD), the lack of early and valid treatment response biomarkers (measurable in the…
Abstract Number: 2045 • ACR Convergence 2024
Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease
Vineetha Philip¹, Soudabeh Daliri², Alma Aveytia Camacho², Ruba Memon³, Myriam Guevara² and Sarah Kazzaz⁴, ¹Houston Methodist Hospital, Sugar Land, TX, ²Houston Methodist, Houston, TX, ³Houston Methodist, Missouri City, TX, ⁴Houston Methodist Hospital, Houston, TX
Background/Purpose: IgG4 – Related Disease (IgG4-RD) is a multisystem immune-mediated fibroinflammatory disorder that can affect nearly any organ and can mimic other inflammatory conditions, malignancy…
Abstract Number: 2280 • ACR Convergence 2024
Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
Peter C. Taylor¹, Kevin Lai², Hsin-Ta Wu², Jason Carlson², Diana Abdueva³, Signe Fransen⁴, Alan Kivitz⁵, Gordon Lam⁶ and David Chernoff⁷, ¹University of Oxford, Oxford, United Kingdom, ²Aqtual Inc, Hayward, CA, ³Aqtual Inc., Hayward, CA, ⁴Aqtual Inc., sf, CA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Matching most beneficial targeted therapy to rheumatoid arthritis (RA) patients with inadequate response or intolerance to current treatment is an important unmet clinical need. The…
Abstract Number: 2456 • ACR Convergence 2024
High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis
François Maillet¹, Carine Schmidt¹, Vincent Bondet², Alexandre Bense¹, Darragh Duffy³, Luc Mouthon¹, Mathieu Paul Rodero⁴ and Benjamin Chaigne⁵, ¹AP HP, Paris, France, ²INSERM PAsteur Institute, Paris, France, ³Inserm Pasteur Institue, Paris, France, ⁴Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 0066 • ACR Convergence 2024
Association Between Gut Microbiota, Inflammation, and Epigenetics in Rheumatoid Arthritis Patients
jose Manuel Lisbona-Montañez¹, Arkaitz Mucientes², Patricia Ruiz-Limón³, Gracia María Martín-Nuñez⁴, Rocio Redondo-Rodríguez⁴, Laura Cano-García⁴, Sara Manrique-Arija⁵, Isabel Moreno-Indias², Natalia Mena Vázquez⁶ and Antonio Fernández-Nebro⁷, ¹University of Malaga, Malaga, Andalucia, Spain, ²IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴IBIMA Plataforma Bionand, Malaga, Spain, ⁵Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁶IBIMA, Málaga, Andalucia, Spain, ⁷Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not entirely known. Epigenetic modifications could be the link between genetic and environmental factors related to the…
Abstract Number: 0392 • ACR Convergence 2024
Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Geoffrey Thiele¹, Panteha Hayati Rezvan², Michal Cidon², Carlos Hunter³, Michael Duryee³, Ted Mikuls³ and Geoffrey Thiele³, ¹Children's Hospital of Los Angeles, Omaha, NE, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0666 • ACR Convergence 2024
Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
Cuiling Fan¹, Shixian Chen² and Juan Li¹, ¹Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), ²Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
Abstract Number: 0803 • ACR Convergence 2024
Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
Anna Haggart¹, Joshua Baker², Tate Johnson³, Yangyuna Yang³, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Dana Ascherman⁸, Paul Monach⁹, Gail Kerr¹⁰, Andreas Reimold¹¹, Michael Duryee³, Geoffrey Thiele³, Ted Mikuls³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Dallas VA Medical Center, Dallas, TX
Background/Purpose: Adipokines are metabolic cytokines shown to be dysregulated in RA and prognostic of RA-related complications such as cardiovascular disease. Similarly, aberrations in adipokines have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.